article thumbnail

FTC order could ease biopharma competition

European Pharmaceutical Review

The biopharma company will be required to seek prior approval before acquiring related products. to address the potential competitive harm Amgen’s $27.8 We believe the government can protect competition while enhancing the value of biotech M&A activity,” John Delacourt, Deputy General Counsel for BIO declared.

article thumbnail

Innovation key for boosting UK biopharma competitiveness

European Pharmaceutical Review

New recommendations to boost the competitiveness in UK biopharma and Medtech sectors have been published by Imperial College London. The ‘Sectoral Systems of Innovation and the UK’s Competitiveness’ reports assess the value-added per capita of each sector and how they compare internationally.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

JPM24: Amgen CEO hopes to take a bite of competitive obesity market with unique approach

Fierce Pharma

After last year saw the rise of popular obesity treatments, biopharma's interest in the field only appears to only be growing. With Novo Nordisk and Eli Lilly dominating the obesity field, Amgen's CEO Robert Bradway knows a new offering will have to offer a unique benefit.

article thumbnail

Biosimilar Insulins Promise Patients New Choices, But Competition Is Still Lacking

MedCity News

The big three insulin manufacturers have cut prices across their product lineups, but potential competition from other biosimilar insulins is still in earlier stages of development. Insulin prices have long been a pain point for diabetics.

article thumbnail

Navigating the Challenges of Biopharma Product Launches: A Blueprint for Success

PM360

Embarking on the journey from product development to market success in the biopharma industry is no small feat. The landscape is highly competitive with new prescription medications launching worldwide each year. However, this journey is fraught with challenges as revealed by an in-depth analysis.

article thumbnail

Eli Lilly Fatty Liver Drug Posts Promising Early Data, But Field Is Still Competitive

MedCity News

However, the Phase 2 results showed only “clinically meaningful” improvement in resolving liver fibrosis, a key measure of the drug’s potential competitiveness in a crowded field of contenders. Eli Lilly reported 74% of patients treated with tirzepatide achieved resolution of metabolic dysfunction-associated steatohepatitis, or MASH.

article thumbnail

Why prefilled vial capacity is key to a competitive edge in pharmaceuticals manufacturing 

Pharmaceutical Technology

With many biopharma companies outsourcing for manufacturing support, how can your organisation outpace the competition?